Regeneron Reports Positive Phase 2 Data for Pozelimab in PNH
December 05 2019 - 9:40AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) on Thursday reported
positive topline phase 2 data for pozelimab in patients with the
rare blood disorder paroxysmal nocturnal hemoglobinuria, or
PNH.
The Tarrytown, N.Y., biotechnology company, said results from
initial six-patient cohort show pozelimab reduced the abnormal
destruction of red blood cells, known as hemolysis, with patients
achieving normal levels of a blood biomarker of elevated hemolysis
called lactate dehydrogenase.
Regeneron said it has initiated the second part of the phase 2
trial, adding that plans for a phase 3 program are underway.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 05, 2019 09:25 ET (14:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024